First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. This study was de...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Zhou, Zhen, Luo, Xia, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724566/
https://www.ncbi.nlm.nih.gov/pubmed/34992538
http://dx.doi.org/10.3389/fphar.2021.788569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724566/
https://www.ncbi.nlm.nih.gov/pubmed/34992538
http://dx.doi.org/10.3389/fphar.2021.788569

Ejemplares similares